Physician profile
Aya Werra
NPI 1093340770
$9,453.52
in general payments reported to CMS, 2019-2025
23 companies · $2,156 in 2025
The $2,156 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,170 · 2023: $2,771 · 2024: $2,356 · 2025: $2,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,219 · Education: $34.10 · Consulting Fee: $30.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,219.29 |
| Education | $34.10 |
| Consulting Fee | $30.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,002.76 | 2022-2025 | Cabenuva, Dovato, Apretude |
| Abbvie INC. | $1,441.64 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $943.24 | 2022-2025 | Pifeltro, Dificid, Delstrigo |
| Melinta Therapeutics, LLC | $878.14 | 2022-2025 | Rezzayo, Kimyrsa, Vabomere |
| Gilead Sciences, INC. | $734.48 | 2022-2025 | Veklury, Biktarvy |
| Shionogi INC | $619.00 | 2022-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $517.21 | 2022-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $366.78 | 2022-2025 | Xacduro, Xerava, Zevtera |
| Theratechnologies INC. | $312.31 | 2022-2024 | Egrifta, Trogarzo, Egrifta Sv |
| Ferring Pharmaceuticals INC. | $95.48 | 2022-2025 | Rebyota |
| Janssen Biotech, INC. | $90.46 | 2022 | |
| Janssen Products, LP | $69.99 | 2022 | |
| Napo Pharmaceuticals INC | $61.39 | 2023 | Mytesi |
| Insmed, INC. | $59.61 | 2024-2025 | Arikayce |
| Pfizer INC. | $47.56 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $41.94 | 2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $32.22 | 2023 | |
| Adma Biomanufacturing LLC | $30.21 | 2025 | |
| Solventum Corporation | $26.87 | 2024 | Activ.A.C. |
| Astellas Pharma US INC | $24.12 | 2025 | Cresemba |
| Emd Serono, INC. | $23.17 | 2025 | |
| Tactile Systems Technology INC | $17.65 | 2024 | Entre Plus, Flexitouch Plus |
| Abiomed | $17.29 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aya Werra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.